{"name":"Mainz Biomed","slug":"mainz-biomed","ticker":"MYNZ","exchange":"NASDAQ","domain":"mainzbiomed.com","description":"Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.","hq":"Mainz, Germany","founded":0,"employees":"19","ceo":"Guido Baechler","sector":"Molecular Diagnostics / Cancer Screening","stockPrice":0.84,"stockChange":0.02,"stockChangePercent":2.44,"marketCap":"$11M","metrics":{"revenue":4200000,"revenueGrowth":-44.9,"grossMargin":67.5,"rdSpend":4905791,"netIncome":-16210718,"cash":1911069,"dividendYield":0,"peRatio":-1.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Mainz Biomed Receives FDA Breakthrough Device Designation for Epi proLung","summary":"Mainz Biomed announced that the FDA has granted Breakthrough Device Designation to Epi proLung, a liquid biopsy test for early-stage lung cancer.","drugName":"Epi proLung","sentiment":"positive"},{"date":"2023-11-14","type":"deal","headline":"Mainz Biomed Announces Collaboration with Leading Cancer Research Institute","summary":"Mainz Biomed announced a collaboration with a leading cancer research institute to advance the development of Epi proLung.","drugName":"Epi proLung","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQNFpha0RtdXZxZlNuTjlJQmZfeTFPWGFtdzF4VlVHTk1WTURsb0VkM1ZzQ3RyNmVnTDQ2NktGU09KdFhzRm5DeEk0Z1NoRGxEQmdvdHZWaXFwZzhBQ3hTLTNNMFlvOU1CVW5YRnJUM281bzhLUVVJQlRIcEJzQnBSejJzSTRzQ0FLTm9rZEx6c0pIc0lUZnc4MGJWNUt2NkhkenFqZUpn?oc=5","date":"2026-03-31","type":"pipeline","source":"Stock Titan","summary":"Mainz Biomed (NASDAQ: QUCY) takes $16.2M loss and plans major Lazar-led recapitalization - Stock Titan","headline":"Mainz Biomed (NASDAQ: QUCY) takes $16.2M loss and plans major Lazar-led recapitalization","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBOUWNXT3RBNXprbVNPV0VDVy1semJjM3JaaFh2YWg5blUyOEFVSFJmeDZmQ3JESm4yLXRtQUMtcFJFSndydmd3VFBJdFpKb2QyXzhn?oc=5","date":"2026-03-13","type":"pipeline","source":"Stock Titan","summary":"QUCY Stock Price, News & Analysis - Stock Titan","headline":"QUCY Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOd1FfQ1VaMGQ3ZWRUWF8wN1VmS2M5ZGl1UkZhQ1J4QmNKaW1fTFdVbW4tbDhKQ2dhdGtha0pFcXNOY19tNVJYdy14ajZzcE93S0Nmby03c0FIelkwLVpjMlAtU0YyMDB4Y3ZfWkRGTzFDOE9XWVQ0akozTUZkbGUxRzlNUWlKeDQ3OXdRSklXX0ZGVF9iTWFqOVgxZHpfR1NKMnhvc2VmUnpnUkxvVFpUOERNSUJBNzAzTjhYaGtB?oc=5","date":"2026-03-11","type":"pipeline","source":"Stock Titan","summary":"First DHS infrastructure protection chief to chair Mainz Biomed - Stock Titan","headline":"First DHS infrastructure protection chief to chair Mainz Biomed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOUWRZdmdPVDdTOWhteHllTkxTMXRfUEczRE01UkxmUFE2MkQ5OHJ3aWNKWGUwU2RGWHF6dXZQRWY3QlJvWncwbjR6b0FpRXBwajBZZTFkOUdHZnRrdlJ2Wll4bURzOUV1Smo4czRWUGhLbjc2YWM3Y3lfckQtNUlnX2UzWGhJbkV2OHpSTVU0aG5ialZGczhYQ1ljUF93N3Joc0hGWnAzSU93QlVPTTYzSlRkc3J4dE9tY1JnNXJFWklYSFpJdHZfY3pkM3FuSTlpZkFwckxFU0MwbDRwUTFERnNYNE96QzJvU1BTUk10QmN2M0lVMV9n?oc=5","date":"2026-03-11","type":"pipeline","source":"globenewswire.com","summary":"Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors - globenewswire.com","headline":"Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNTFBkX1gyUGNGREU2Z2V4S20ybFZqVEVvWFRUWVFBMlBaRC1Wak8wNlo4d0l2NzBONmx0dk1mTDNyQjAzY2d1cjRyZzJSNFRfYVRtN2piYmZrcXR1TWJnMVByejFYbEd0YXRZeVBQbGRHbXg3Z1lwMkJOQ3prZTRIOWZRaGYtQTJiNlhESlhjZGtOcHozeEJJWF9ETmVuLWw2ODg0bGMxakxrTUdXbWF6dVBVS00?oc=5","date":"2026-02-24","type":"pipeline","source":"Stock Titan","summary":"Blood test flags pancreatic cancer with 100% sensitivity, Mainz says - Stock Titan","headline":"Blood test flags pancreatic cancer with 100% sensitivity, Mainz says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPS2E0MkdoQVVONGYzMnF3cTVYQ3A3MmpiMEZHUXZwazRra2I3SVBreVMzbDZuWVlwVkZfSmJkYmJHX0pjQk5ZckFlNGpPVmdrUXJaQmtUY1p2NTFPVFFrbjFUQld1bjc1ZUhCaXFCRks0dmlDdHMxbGIwcmxlSk5Rd1A4c2ZBSTJ5bmhyb1gwNUpOczl3Z1FlWnZDR29xQ1FYUktzYWpHQ1g?oc=5","date":"2026-02-17","type":"deal","source":"Stock Titan","summary":"6.0 USD million deal puts Mainz Biomed (NASDAQ: MYNZ) on new path - Stock Titan","headline":"6.0 USD million deal puts Mainz Biomed (NASDAQ: MYNZ) on new path","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOa2JwV2ljQ1p5STNRZXlZNHEwTkY5aGRlQ2N5bzFuR0N6SUNHLU1FR2l6ZlM0WnFURlliRi1EUUZzbEFqNk55cU9ubzd5eE93Q1JXcG5YaTRJUDQ2LWF0Nk9FSXdKY01YemRmY1lCN3hhTndmT2Z6Yml5c2VoOW9yaktvRkI5MGV4WHRxRTlXdmwxQTFSbE5wUTF3STI5ZjZoUUkxU3RJLU5pNmM0OW5ydWhCbHFvVWtiaVNYQlNPa2pYN1FXV3o0dUs1ZzRPZlhYRUhFaUZYbzlWZW0wNHlSQi13eTJ5QTg4RWJVbHNoUUM0S2p5a0pzVE9Wb05rRExq?oc=5","date":"2026-01-14","type":"trial","source":"globenewswire.com","summary":"Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting - globenewswire.com","headline":"Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPekZkbUpwYlhsZkpCZlRDTjdrZXNwR19MWHRZcVAwZF9vbjk4VVZOUDZaNm5hZzVJME9jY19HdTNFV0U3LWxNN0FfeXRlYXpFTTVSWmZmbmZvTTduZXJWTTFHRGhjcGlrVTNwWm9Jb3BQY0Zvb2Jtc1oySU5YdXpwNG9qNmJsMk1CWlZwSDV0alVfOWZ4U2J3OE53?oc=5","date":"2025-12-12","type":"pipeline","source":"MarketBeat","summary":"2 Small-Cap Biotechs That Could Reward Patient Investors - MarketBeat","headline":"2 Small-Cap Biotechs That Could Reward Patient Investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE13TEhiM2ZsZnh6NDF2eXRiSjcxNnl3bTlqSmloMEozNnBEVGctM2xNSnAzYlpURHRYVG5heGhMSlRYOERfUXFiLUI5a3k3UUxwNWQxcFRpU3dEQQ?oc=5","date":"2021-11-06","type":"pipeline","source":"MarketBeat","summary":"Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat","headline":"Mainz Biomed (MYNZ) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Exact Sciences","Invitae","Foundation Medicine"],"therapeuticFocus":["Oncology","Molecular Diagnostics"],"financials":{"source":"sec_edgar+yahoo","revenue":537080,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":537080,"period":"2025-12-31"},{"value":893991,"period":"2024-12-31"}],"grossProfit":389792,"grossProfitHistory":[],"rdSpend":4905791,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-16210718,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":5327396,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":19,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.84,"previousClose":0.82,"fiftyTwoWeekHigh":5.34,"fiftyTwoWeekLow":0.55,"fiftyTwoWeekRange":"","fiftyDayAverage":0.92,"twoHundredDayAverage":1.35,"beta":0.32,"enterpriseValue":4285799,"forwardPE":-1.1,"priceToBook":1.37,"priceToSales":16.01,"enterpriseToRevenue":6.49,"enterpriseToEbitda":-0.27,"pegRatio":0,"ebitda":-16145343,"ebitdaMargin":0,"freeCashflow":-8186486,"operatingCashflow":-15461421,"totalDebt":3093607,"debtToEquity":122.6,"currentRatio":0.52,"returnOnAssets":-114.4,"returnOnEquity":0,"analystRating":"","recommendationKey":"hold","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":17.4,"institutionHeldPercent":13.1,"sharesOutstanding":12515336,"floatShares":3459866,"sharesShort":467577,"shortRatio":0.82,"shortPercentOfFloat":3.7,"epsTrailing":-5.28,"epsForward":0,"revenuePerShare":0.29,"bookValue":0.62,"officers":[{"age":60,"name":"Mr. Guido  Baechler","title":"CEO & Executive Director"},{"age":58,"name":"Mr. William J. Caragol CPA","title":"CFO & Senior VP"},{"age":53,"name":"Dr. Christopher  Von Toerne P.M.P., Ph.D.","title":"Chief Operating Officer"},{"age":null,"name":"Mr. Stefan  Erlach","title":"Head of Human Resources"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://mainzbiomed.com","phone":"49 6131 554 2860"}}